Health Discovery EBIT per Share
EBIT per Share of Health Discovery (HDVY) as of Aug 10, 2026.
Get this data via API
Financial Data API
EBIT per Share
0.00USD
Last updated:
EBIT per Share of Health Discovery is 2026 0.00 USD. EBIT per Share of Health Discovery was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Health Discovery Stock analysis
What does Health Discovery do? Health Discovery Corp (HDC) is a company specializing in the development of novel diagnostic technologies for cancer early detection and prevention. The company was founded in 2003 and is headquartered in Savannah, Georgia.
History
HDC began its operations as a research laboratory at the University of Georgia and the Georgia Institute of Technology. Since then, the company has developed numerous patents and technologies, including a new method for identifying gene expression profiles and the development of data mining software that allows for the identification of genetic patterns associated with various types of cancer.
Business model
HDC's business model is based on the development and commercialization of diagnostic tests and screening tools that help physicians and patients identify cancer at an early stage. The company works closely with research and development departments at hospitals and universities to develop and bring new technologies and tests to market.
Segments
HDC has divided itself into different segments to focus on specific technologies and applications. The key segments of HDC are:
1. Biomarker development: This segment of HDC focuses on the identification of biomarkers that can serve as markers for the presence of cancer in the body.
2. Women's health products: HDC has developed products and tests specifically targeting women, including a blood test for early detection of ovarian cancer and a digital breast examination device to improve breast cancer diagnostics.
3. Software solutions: HDC has developed data mining software that can identify genetic patterns associated with specific types of cancer. The software is used by researchers and scientists in cancer research.
Products
The company has developed a range of innovative products to help physicians and patients detect cancer at an early stage and take preventive measures. Some of HDC's key products include:
1. MelApp: A smartphone app that allows users to take photos of skin lesions or moles and analyze them for the presence of melanomas.
2. VitalSines BodyTel: A digital breast examination device designed to help physicians detect breast cancer at an early stage by identifying changes in breast structure and density.
3. Ovarian Cancer Early Detection Test: A blood test specifically targeting the early detection of ovarian cancer, with high accuracy.
In summary, HDC specializes in the development of innovative technologies for cancer prevention and early detection. The company works closely with academic and clinical research and has specialized in various technologies and applications, including biomarker development, women's health products, and software solutions. Some of the company's key products include MelApp, VitalSines BodyTel, and the Ovarian Cancer Early Detection Test. Health Discovery is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Health Discovery stock
On Eulerpool you can find the complete historical development of EBIT per Share Health Discovery since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Health Discovery
All Key Metrics — Health Discovery
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth